Watermark
Go to Asia edition

Alizyme

  • 22 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • 19 Sep 2019
1 JPMorgan 299,908.40 1348 8.58%
2 Citi 269,633.69 1139 7.71%
3 Bank of America Merrill Lynch 233,702.48 955 6.69%
4 Barclays 215,977.22 873 6.18%
5 Goldman Sachs 171,316.37 716 4.90%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 BNP Paribas 34,547.72 148 7.49%
2 Credit Agricole CIB 33,319.19 143 7.23%
3 JPMorgan 25,404.62 68 5.51%
4 Bank of America Merrill Lynch 23,368.44 65 5.07%
5 SG Corporate & Investment Banking 22,565.04 105 4.89%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 9,273.57 56 10.30%
2 Morgan Stanley 8,122.33 40 9.02%
3 Goldman Sachs 7,738.32 41 8.59%
4 Citi 6,426.54 47 7.14%
5 UBS 4,913.18 26 5.46%